Synexa Life Sciences Expands Biomarker Discovery Capabilities with the Addition of Olink® Target Platform

The addition of Olink to the Synexa Life Sciences technology portfolio demonstrates our continued commitment to strengthening our biomarker and bioanalysis capabilities across several expertise areas including oncology, immuno-oncology, infectious diseases and more.